Palatin Technologies shares are trading lower after the company announced results for its PL9643 MELODY-1 Pivotal Phase 3 clinical trial in patients with dry eye disease did not meet co-primary sign endpoints and secondary sign endpoints.
Portfolio Pulse from Benzinga Newsdesk
Palatin Technologies announced that its PL9643 MELODY-1 Pivotal Phase 3 clinical trial for dry eye disease did not meet its primary or secondary endpoints, causing its shares to trade lower.
February 28, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Palatin Technologies' shares are trading lower following the announcement of disappointing results from its PL9643 MELODY-1 Phase 3 clinical trial for dry eye disease.
The failure of the PL9643 MELODY-1 Phase 3 clinical trial to meet its primary and secondary endpoints is a significant setback for Palatin Technologies, likely leading to decreased investor confidence and a drop in share price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100